Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Aren’t You Glad 2020 Is Over? A Look Back (and Ahead)

main

01_14_Arent you glad 2020 is over

Learn more about the Federal Circuit and Supreme Court patent cases that you may have missed in our presentation looking back at 2020.

Aren’t You Glad 2020 Is Over? A Look Back (and Ahead)

Contacts

Darryl M. Woo

Andrew Ong

Related Content

USPTO Issues New Guidance on Patenting AI-Assisted Inventions

The USPTO’s Increasing Focus on FDA Submissions and the Duty of Disclosure

Chief Judge of Western District of Texas Changes Waco Patent Case Assignment System

Fintiv 2.0: USPTO Director Issues Guidance Softening Risk of Discretionary Denial

Federal Circuit Clarifies Standard for Fair and Reasonable Exercise of Jurisdiction Based on Demand Letters

Federal Circuit Narrows Venue for Patent Infringement Suits Under the Hatch-Waxman Act

Strategic Considerations for Seeking Patent Term Extension (PTE) and its Scope for Drug Products

Webinar Recording:
Law and Pop Culture

PLI's Patent Law Institute 2024: Critical Issues & Best Practices San Francisco

IP Leadership Executive North America 2024

The Fate of the Therapeutic Dosing Regimen: Trends and Considerations in Validity Challenges to Dosing Patent Claims

Updates on the Drug Price Negotiation Program of the Inflation Reduction Act: An Overview of Recent Court Decisions, the Status of Remaining Challenges, and the Status of “Negotiations”

Abortion at the Supreme Court (Again)

BBA's IP Year In Review Conference

ACS Spring 2024: Many Flavors of Chemistry

Utah Bar Association – Intellectual Property Law Summit

Patent Litigation

Patent Prosecution & Counseling

Patent Trial & Appeal Board

Aren’t You Glad 2020 Is Over? A Look Back (and Ahead)

Contacts

Darryl M. Woo

Andrew Ong

Related Content

USPTO Issues New Guidance on Patenting AI-Assisted Inventions

The USPTO’s Increasing Focus on FDA Submissions and the Duty of Disclosure

Chief Judge of Western District of Texas Changes Waco Patent Case Assignment System

Fintiv 2.0: USPTO Director Issues Guidance Softening Risk of Discretionary Denial

Federal Circuit Clarifies Standard for Fair and Reasonable Exercise of Jurisdiction Based on Demand Letters

Federal Circuit Narrows Venue for Patent Infringement Suits Under the Hatch-Waxman Act

Strategic Considerations for Seeking Patent Term Extension (PTE) and its Scope for Drug Products

Webinar Recording: Law and Pop Culture

Webinar Recording:
Law and Pop Culture